[Federal Register Volume 65, Number 191 (Monday, October 2, 2000)]
[Notices]
[Page 58778]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-25176]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESS: Licensing information and copies of the U.S. patent 
application listed below may be obtained by contacting Susan S. Rucker, 
J.D., at the Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-
3804; telephone: 301/496-7056 ext. 245; fax: 301/402-0220; e-mail: 
[email protected]. A signed Confidential Disclosure Agreement will be 
required to receive a copy of the patent application.

HGF-SF Monoclonal Antibody Combinations

B Cao, S Koochekpou, M Oskarsson, D Bjurickovic, M Fivash, R Fisher and 
GR Vande Woude (NCI)
Serial No. 60/164,173 filed 09 Nov 1999

    The invention described and claimed in this application relates to 
a composition which comprises a combination of two or more antibodies 
which specifically bind one or more epitopes of the growth factor known 
as hepatocyte growth factor/scatter factor (HGF/SF) which is able to 
inhibit HGF/SF signaling. In particular, the antibodies which 
specifically bind to HGF/SF are monoclonal antibodies. Hepatocyte 
Growth Factor (HGF) activates migration and proliferation of 
endothelial cells and is angiogenic, acting through the tyrosine kinase 
receptor encoded by the Met protooncogene. In addition, HGF/SF displays 
a unique feature in inducing ``branching morphogenesis'', a complex 
program of proliferation and motogenesis in a number of different cell 
types. Moreover, HGF is involved in the invasive behavior of several 
tumor cells both in vivo and in vitro. This combination of antibodies 
may be useful in drug screening assays, detection of HGF/SF expression 
or activity or in treating HGF/SF related diseases such as cancer.

    Dated: September 21, 2000.
Jack Spiegel,
Director, Division of Technology Development and Transfer Office of 
Technology Transfer National Institutes of Health.
[FR Doc. 00-25176 Filed 9-29-00; 8:45 am]
BILLING CODE 4140-01-P